We anticipate future investigations to determine if this novel assay is superior to PSA and PCA3 tests, and if its use of a panel of biomarkers makes it more effective in accurately diagnosing aggressive PCa, and distinguishing between indolent and aggressive PCa. This evidence concerns the gene PCA3 and posterior cortical atrophy.